# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Hubert H. Humphrey (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML022-SYN
- Date: 2026-01-06
- Fictional facility: St. Posthumous Health Center
- Fictional author: Walter Brandvold, MD
- Calendar frame: modern shifted

## Subjective

The patient participates in this fictional visit for first visit to establish shared care three months after radical cystoprostatectomy with an ileal conduit for bladder cancer. **S**

## Objective

Sodium: 139 mmol/L; Potassium: 4.3 mmol/L; Chloride: 106 mmol/L; Bicarbonate (total CO2): 22 mmol/L; Urea nitrogen: 18 mg/dL; Creatinine: 1.12 mg/dL; eGFR: 73 mL/min/1.73 m²; Calcium: 9.2 mg/dL; Albumin: 3.7 g/dL; Alkaline phosphatase: 88 U/L; ALT: 22 U/L; Hemoglobin: 12.6 g/dL (low); White cell count: 6.4 10*3/uL; Platelets: 284 10*3/uL; Vitamin B12: 412 pg/mL; PHQ-9: 3. All results are synthetic.

BP 126/76 mmHg; pulse 74 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 97% on room air; weight 76.5 kg; BMI 23.6 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Urothelial carcinoma of the bladder, multifocal, with carcinoma in situ, pT2a pN0 (0 of 18 nodes), margins negative, treated by radical cystoprostatectomy with an ileal conduit; no evidence of disease; under surveillance; synthetic modern detail linked to his documented bladder cancer; Ileal conduit urostomy, right lower abdomen; Acquired absence of the bladder and part of the urethra after radical cystectomy; Acquired absence of the prostate after cystoprostatectomy; Personal history of pelvic radiation for bladder tumor, with earlier intravesical thiotepa. Strengths and supports remain part of the care plan. **S**

## Medication changes

- No medication changes. **S**

## Plan

- Urology consultation to share survivorship surveillance after radical cystectomy, review the stoma, and set the metabolic monitoring plan. Guideline: Holzbeierlein J, et al. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024). J Urol 2024;212(1):3-10 (2024); NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer (2026) **S**
- Stoma care with the wound, ostomy, and continence nurse: appliance fitting, peristomal skin care, and parastomal hernia checks. Guideline: Holzbeierlein J, et al. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024). J Urol 2024;212(1):3-10 (2024); CMID: Clinical Monitoring Intelligence Database, urologic cancer monograph (2026) **S**
- Distress screening at each visit, physical activity, and a written survivorship care plan. Guideline: NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer (2026); CMID: Clinical Monitoring Intelligence Database, urologic cancer monograph (2026) **S**
